MAPS Logo spacer
search
leftspacer middlespacer rightspacer
Support Maps
Participate Menu
Related Material
Features
Free Monthly Newsletter
small arrowMAPS Email News Archive
MAPS Bulletin
 
Participate > MAPS 2010 Conference

Conf2010 Image

Psychedelic Science
in the 21st Century

April 15-18, 2010 in the San Francisco Bay Area

A Continuing Medical Education (CME) Conference open to Physicians, Other Medical Professionals and the General Public


Psychedelic Science will bring together international experts to present on psychedelic research and psychedelic psychotherapy topics for the largest conference dedicated solely to psychedelics in the U.S. in 17 years. There will be three full days of programming with concurrent tracks exploring clinical applications, issues relevant to healthcare professionals, and social and cultural issues surrounding the therapeutic and recreational uses of psychedelics.

Psychedelic Science will offer pre- and post-conference workshops with Stanislav Grof, M.D., Rick Doblin, Ph.D., Michael Mithoefer, M.D., Annie Mithoefer, B.S.N., and others to be determined.

Registration, Lodging, and Dining
contractRegistration and Pricing Information

Registration for Psychedelic Science in the 21st is available through the MAPS webstore. The pricing structure is as follows *:

Registration Class

Early rate ends Dec 31, 2009

Regular Rate

Late rate begins March 15, 2010

Day Rate

General Public

$225

$275

$325

$125

Medical Doctors

$375

$425

$475

$200

Ancillary Medical Professionals

$275

$325

$375

$150

Limited scholarship registration is available for $120.00.

*All prices are for MAPS members. Non-MAPS members pay an additional $50. MAPS members have donated to MAPS within the past 12 months. To become a MAPS member visit: www.maps.org/donate or call MAPS headquarters at 831-429-MDMA (6362).

Medical doctors and other medical professionals pay higher fees in order to receive CME credits. Medical doctors and other medical professional who do not want to receive CME credits are welcome to pay the general admission rate.


contractScholarship Registration Information
 

Scholarship Application Form

Thank you for your interest in attending Psychedelic Science in the 21st Century. MAPS is awarding up to 10 scholarships for each 90 paid registrations. The scholarship registration is to encourage people to attend who might otherwise be unable to attend. This scholarship application will be used to help the Psychedelic Science scholarship committee determine to whom to provide discounted scholarship registrations.

Scholarships will be awarded to people of limited financial means who have a demonstrated interest in psychedelic science or psychedelic psychotherapy. Decisions will be made based on four additional factors of equal consideration. Preference will be given to: 1) people who belong to groups that are historically underrepresented in academic discourse on psychedelics such as women, indigenous people, and people of color, 2) international attendees, students, senior citizens, veterans, disabled persons, or people who have not yet been to a conference on psychedelics, 3) people who have applied to present and been accepted, and, 4) individuals who are representing an allied organization.

The priority deadline for scholarship submission is December 31. If you apply for a scholarship by December 31 and your application is not accepted, we will let you purchase a registration at the early bird price any time before March 15.

We will accept scholarship applications on a rolling basis after December 31. We will reward the next round of scholarships by March 6, 2010, which means that if you are still not awarded a scholarship you can purchase a regular registration before March 15. Scholarship applications submitted after March 6 will be awarded based on availability.

***If you are given the scholarship rate, MAPS will email you a coupon code and a link to a page on the MAPS webstore where you can purchase your registration.***

You will be responsible for your own transportation and lodging during the conference. MAPS is unable to offer any discounts on lodging at the Holiday Inn, but the rooms are reasonably priced and include several meals. If you choose to stay elsewhere, but wish to eat meals at the conference hotel, they can be purchased for $20/meal (this does not include the Shulgin benefit reception on Saturday night). Double occupancy rooms cost $199 at the Holiday Inn and include meals for two people. If you were to share a room with more than two people, then each additional person would need to pay $20/meal in order to dine at conference meals (excluding the benefit dinner on Saturday night).

> Download scholarship application as Adobe PDF. Please email the completed form to conference2010@maps.org.

Your First Name
Your Last Name
Your Email
Phone
City State/Province Postal Code
Country
ProfessionCredentials / Field-of-Study / Other Interests

Scholarship Application:
  Why do you want to attend Psychedelic Science in the 21st Century? (2000 character limit)

(Maximum characters: 2000)
You have characters left.
  Please explain your involvement/interest in psychedelic science or psychedelic psychotherapy (1000 character limit)

(Maximum characters: 1000)
You have characters left.
  Is this your first psychedelics conference?
  Please briefly indicate why you are unable to pay regular priced registration (1000 character limit)

(Maximum characters: 1000)
You have characters left.
  Have you applied to present at Psychedelic Science?
  Would your attendance be on behalf of an organization?
  Which organization?
  What is the organization’s website?
  What is the organization’s operating budget?
  Are others applying from your organization?
  What are their names?
  Are there any other special circumstances we should know about? (1000 character limit)

(Maximum characters: 1000)
You have characters left.
  Do you consider yourself to come from a group of indigenous people or from a first nation?
  How would you describe your ethnic or cultural background? (optional)
  Do you identify yourself as a particular gender? (optional)
  Are you a student?
  If so, where and in which program?
  Are you a senior citizen?
  Are you a veteran?
  Are you on government disability?
  If you were encouraged to apply for a scholarship by a MAPS staff member, please indicate their name here:

Thank you for filling out the scholarship application.


contractConference Hotel Information

The conference will be held at the Holiday Inn San Jose, at 1740 North First Street, San Jose, California.

We strongly recommend that you stay at the Holiday Inn and book your room through our group rate. The room rates are very competitive and are inclusive tax-- rates include most meals during the conference.

If you make your hotel reservation through a third party such as Expedia, you will not be eligible for conference meals. Competitors rates advertised online tend to not include tax until check out.

You can register here for rooms at the conference hotel at our inclusive group rate*, or you can call the Holiday Inn and book your room by mentioning "MAPS Psychedelic Science":

Book single occupancy rooms for $139/night*
Book double occupancy rooms for $199/night*

*Room rates include most meals at the conference.

If you have more than two people in a double occupancy room, the additional people will need to purchase meal vouchers to dine at conference meals.

If you would like to have meals during the conference and choose not to stay at the Holiday Inn, meal vouchers must be purchased ahead of time.

Meal vouchers will be available for purchase for $20/meal at a later date (this does not apply to the benefit dinner on Saturday night).


contractBenefit Dinner Honoring the Shulgins

There will be a special benefit dinner on the evening of Saturday April 17 to raise funds for the conference, with guests of honor Ann and Alexander “Sasha” Shulgin, whose lifetime of achievements are inspiring. As a pharmacologist and chemist Sasha discovered numerous new psychoactive chemicals and authored the legendary books TIHKAL and PIHKAL, and hundreds of other scientific papers. Ann and Sasha are legendary for bringing rational and scientific perspectives to self-experimentation and psychoactive ingestion.

The benefit will cost $60 to attend and is not covered by the cost of the hotel room. Tickets may be purchased for the benefit dinner beginning in mid-October on the MAPS webstore.


Conference Presentation Information
contractCME Objectives and Accreditation

International experts will present the state of the art of psychedelic science and psychedelic psychotherapy studies, including:

  • Biological and neurological effects of psychedelic substances
  • MDMA-(ecstasy) assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD)
  • Psychedelic psychotherapy for treating anxiety and depression associated with life-threatening illnesses
  • Mystical-type experiences catalyzed by psychedelics and their therapeutic implications
  • Psychedelics’ role in the treatment of drug addiction
  • Psilocybin research with obsessive-compulsive disorder
  • Standards for conducting psychedelic psychotherapy research

The intended learning objectives for medical doctors and ancillary medical professionals are:

1) Apply new techniques and strategies for enhancing communication, trust and therapeutic effectiveness with patients in their regular therapeutic practices, based on transferable lessons learned from presentations about recent psychedelic research and associated psychedelic psychotherapy techniques.
2) Counsel patients and their families more effectively with drug-related issues and/or questions by implementing knowledge of recent scientific research about the mechanisms of action and potential risks and benefits of psychedelic drugs.
3) Make informed decisions about initiating and/or improving their own clinical research with psychedelics, by having additional information on special regulatory issues, current research methodologies and therapeutic approaches.
4) Evaluate methodological rigor of clinical trials of psychedelic-assisted psychotherapy, and research in general, in light of presentations about the design of state-of-the-art research in the field.
5) Implement compassionate psychedelic psychotherapy intervention techniques in emergency room situations and in private practice when attending to patients undergoing acute psychedelic crises.
6) Refer patients with relevant medical conditions to active clinical trials.
7) Post conference, be able to share with colleagues knowledge from recent scientific studies pertaining to the medical and non-medical use of psychedelic drugs.

This activity has been planned and implemented in accordance with the Institute for Medical Quality and the California Medical Association’s CME Accreditation Standards (IMQ/CMA) through the Joint-Sponsorship of CME Consultants and the Multidisciplinary Association for Psychedelic Studies (MAPS). CME Consultants is accredited by IMQ/CMA to provide continuing medical education for physicians. CME Consultants takes responsibility for the content, quality and scientific integrity of this CME activity.

CME Consultants designates this educational activity for a maximum of 15.0 AMA PRA Category 1 Credit™.  Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.


contractPresenters confirmed for the CME Track

Presenters in the CME track (in alphabetical order):

Matt Baggott, Ph.D. Candidate, University of California Berkeley
A graduate student at the Helen Wills Neuroscience Institute at University of California Berkeley and research associate at the California Pacific Medical Center Research Institute, Matt Baggott’s professional interests bridge neuroscience and psychopharmacology, and include mechanisms of hallucinations, toxicity of drugs of abuse, pharmacokinetics and dynamics of phenethylamines, and neural correlates of consciousness. His most recent studies are centered on Hallucinogen Persisting Perception Disorder (HPPD).

Jose Carlos Bouso, Ph.D. Candidate
Jose Carlos Bouso’s studies addressed the safety of different doses of MDMA administered in a psychotherapeutic setting to women with chronic posttraumatic stress disorder (PTSD) secondary to a sexual assault. He also obtained initial data on the efficacy of MDMA-assissted psychotherapy. He currently works on Dr. Riba's team conducting neuropharmacological research on psychedelics.

Alicia Danforth, Ph.D. Candidate
A graduate student of clinical psychology and a research associate and co-facilitator for the Harbor-UCLA cancer anxiety trial with psilocybin, Alicia Danforth will provide an overview of the research from the late 1950s through the early 1970s on the use of LSD and psilocybin in the treatment of severe autism in children. She will also discuss the potential use of MDMA-assisted therapy as a supplement to treatment for individuals with high-functioning autism and Asperger syndrome.

Peter Gasser M.D.
Dr. Gasser will present data on an on-going randomized, double-blind, placebo-controlled study of LSD-assisted psychotherapy in subjects with anxiety associated with end-of-life issues. This study will be completed in 2010 and will become the first study of LSD-assisted psychotherapy in human subjects in over 35 years.

Roland Griffiths Ph.D.
Dr. Griffiths, a professor in the departments of Psychiatry and Neuroscience at Johns Hopkins University, has had a principal research focus in both clinical and preclinical laboratories on the behavioral and subjective effects of mood-altering drugs. He will present research investigating psilocybin-induced mystical experiences in psychedelic naïve adults and psilocybin induced-mystical experiences in volunteers with cancer.

Charles Grob M.D.
Dr. Grob will discuss a completed, randomized, double-blind, placebo-controlled study of psilocybin-assisted psychotherapy in subjects with anxiety associated with cancer. A paper about this study was submitted for publication in August 2009. His talk will also cover the psychobiologic effects of MDMA in humans, the MDMA-neurotoxicity controversy, the effects of MDMA on cerebral blood flow, and the neuropsychological effects of MDMA in recreational users.

Stanislav Grof M.D.
A pioneer researcher of the use of altered states of consciousness for purposes of analyzing, healing, and obtaining growth and insight into the human psyche, and one of the founding fathers of the field of transpersonal psychology, Dr. Stanislav Grof will be discussing LSD-assisted psychotherapy in patients with terminal cancer, the experimental use of psychedelic psychotherapy, the conceptual challenges from researching consciousness, and DPT as an adjunct in psychotherapy of alcoholics.

John Halpern M.D. (presenting by live video link)
Dr. Halpern will report on an ongoing randomized, double-blind, placebo-controlled study of MDMA-assisted psychotherapy in 12 subjects with anxiety associated with advanced-stage cancer, taking place at McLean Hospital, Harvard Medical School. Data will also be presented from Dr. Halpern’s National Institute on Drug Abuse-funded 5-year controlled, blinded study of the neurocognitive effects of Ecstasy use. Preliminary data from this study has also been published and includes the psychological and cognitive effects of long-term peyote use among Native Americans and evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.

Julie Holland, M.D.
Dr. Holland will present lessons she learned in a psychiatric emergency room at Bellevue Hospital, NYC. Dr. Holland, editor of Ecstasy: A Complete Guide, will also speak about the potential therapeutic use of MDMA in the treatment of schizophrenia.

Sergio Marchevsky M.D.
Dr. Marchevsky will report on data from an on-going randomized, double-blind, placebo-controlled study of MDMA-assisted psychotherapy in subjects with treatment-resistant PTSD, taking place at Beer Yaakov Mental Health Center in Israel.

Michael Mithoefer M.D.
Dr. Mithoefer, will report on data from the completed, randomized, double-blind, placebo-controlled pilot study of MDMA-assisted psychotherapy in 21 subjects with treatment-resistant PTSD, and on the subsequent long-term follow up of these subjects > 1 year after study completion. He will also describe the design and progress of a dose-response MDMA-assisted psychotherapy study in US war veterans that he expects to complete in 2011.

Francisco Moreno M.D.
An Associate Professor of Psychiatry at the University of Arizona College of Medicine, Dr. Moreno has been conducting research in biology and treatment of mood and anxiety disorders, geared to improve our understanding of the brain basis for mental illness and the underlying mechanism of action of antidepressants/anti-anxiety drugs, and treatment resistance. He will be discussing, among other things, the safety, tolerability, and efficacy of psilocybin in patients with Obsessive-Compulsive Disorder (OCD). His recent research concluded that there were acute reductions in core OCD symptoms in a number of subjects.

David Nichols Ph.D.
The founding president of the Heffter Research Institute and Distinguished Chair in Pharmacology at Purdue University, Nichols is considered to be one of the world's top experts on psychedelics. His recent studies investigate the phylogeny and structure of serotonin receptors, their signaling systems and receptor oligomerization. The general theme of his research is to understand how changes in brain neurochemistry affect behavior, through the use of molecular probes. His laboratory has published numerous studies elucidating details both of the mechanism of action of MDMA and of the biochemical events related to the neurotoxic effects seen in animals following administration. Dr. Nichols coined the name 'entactogen' to describe the unique psychopharmacological effects of MDMA and related compounds.

Peter Oehen M.D.
Dr. Oehen will report on data from an on-going randomized, double-blind, placebo-controlled study of MDMA-assisted psychotherapy in 12 subjects with treatment-resistant PTSD. The 12th subject has recently been enrolled into the study, which will conclude data-gathering around January 2010.

Torsten Passie M.D. Ph.D.
Scientific collaborator and psychiatrist at Medical School Hannover’s Department of Clinical Psychiatry and Psychotherapy, Dr. Passie will cover neuropsychological research with MDMA, LSD and psilocybin, the psychopharmacological effects of Ketamine and nitrous oxide on human subjects, and MDMA’s impairment of sexual drive and function due to increased prolactin secretion.

Jordi Riba M.D.
Dr. Riba conducted the first controlled pharmacological study of ayahuasca in experienced psychedelic users. These studies have assessed the general pharmacology of ayahuasca in humans, including alkaloid disposition, and electroencephalography and neuroimaging measures of acute ayahuasca effects. The results of these studies have been published in various scientific journals like Psychopharmacology, Journal of Pharmacology and Experimental Therapeutics, British Journal of Clinical Pharmacology and Journal of Psychoactive Drugs. He is currently conducting a neuropsychological study assessing the effects of long-term ayahuasca use.

William Richards, Ph.D.
William A. Richards, Ph.D. is a psychologist in the Psychiatry Department of the Johns Hopkins University School of Medicine, Bayview Medical Center. His graduate degrees include a Master of Divinity from Yale Divinity School, a Master of Sacred Theology (S.T.M.) from Andover-Newton Theological School, and a Ph.D. from Catholic University. Richards also studied with Abraham Maslow at Brandeis University and with Hanscarl Leuner at Georg-August University in Goettingen, Germany, where his involvement with psilocybin research originated in 1963. From 1967 to 1977, Richards pursued psychotherapy research with LSD, DPT, MDA and psilocybin at the Maryland Psychiatric Research Center. His research included protocols designed to investigate psychedelics as a treatment for alcoholism, severe neuroses, narcotic addiction, and the psychological distress associated with terminal cancer, and also their use in the training of religious and mental-health professionals. He helped design and served as the primary guide in the John Hopkins research that demonstrated the positive correlation between psilocybin and mystical experiences (see Griffiths, et al. 2006).

Stephen Ross, M.D.
Stephen Ross, M.D. is Principal Investigator of the new Psilocybin Cancer Project at NYU. He is Assistant Professor of Psychiatry and Oral Medicine at the NYU School of Medicine and College of Dentistry. Dr. Ross completed general psychiatry training at Columbia University/New York State Psychiatric Institute, and received addiction psychiatry fellowship training at Bellevue Hospital & the NYU School of Medicine. Currently, Dr. Ross is the Director of the Division of Alcoholism & Drug Abuse at Bellevue Hospital, the Clinical Director of the NYU Langone Center of Excellence on Addiction, and the Associate Director of Addiction Education, NYU Department of Psychiatry. He has received eight teaching awards relating to education of medical students, general psychiatry residents, and addiction psychiatry fellows. His research focuses on co-occurring disorders, personality disorders, music therapy, public health, and the therapeutic application of hallucinogens.

Franz Vollenweider M.D.
During the past ten years, Dr. Vollenweider has established a research program aiming to understand the neural basis of altered states of consciousness in health, schizophrenia, and affective disorders. Dr. Vollenweider’s research interests have increasingly focused on the understanding of the neural basis of drug (e.g. psychedelic) and non-drug (e.g. pathological) - induced altered states of consciousness. In search of the neuronal correlates of altered states, the subjective and neurobiological effects of classic hallucinogens, dissociative anesthetics and psychostimulants have been assessed in more than 500 healthy human volunteers using neuropsychological and brain imaging methods such as positron emission tomography and high density electroencephalography, and measures of information processing. Dr. Vollenweider’s research has been continuously funded by the Swiss National Science Foundation, Swiss Federal Health Office, and the Heffter Research Institute (USA). He has published over 100 peer-reviewed papers, including many addressing the mechanisms sub-serving the effects of psychostimulants, hallucinogens, and entactogens.

Andrew Weil M.D. (presenting by live video link)
Andrew Weil, M.D., is a world-renowned leader and pioneer in the field of integrative medicine, a healing oriented approach to healthcare, which encompasses body, mind, and spirit. Dr. Weil is the founder and director of the Arizona Center for Integrative Medicine (AzCIM) at the University of Arizona Health Sciences Center, where he is also a Clinical Professor of Medicine and Professor of Public Health and the Lovell-Jones Professor of Integrative Rheumatology.

Michele Weitz, BA
Michelle Weitz has 15 years experience in a clinical research setting and is an expert on good clinical practice for pharmaceutical research. She designs and evaluates quality assurance infrastructure and clinical operation processes to prepare researchers for inspections by regulatory agencies. She will provide training for investigators who are interested in conducting clinical trials of psychedelic therapy in line with international standards for pharmaceutical research.


contractCultural and Psychotherapy (Non-CME) Track

The cultural and psychotherapy track will have presentations on issues surrounding the therapeutic and spiritual uses of psychedelics. The call for proposals to present in this section is currently open (please see the presenter application instructions below).

Confirmed speakers include:

  • Amanda Feilding, (Director of The Beckley Foundation)
  • Frank Echenhofer, Ph.D. (California Institute of Integral Studies)
  • Earth and Fire Erowid (founders of erowid.org)
  • Carolyn Garcia, aka Mountain Girl
  • Neal Goldsmith, Ph.D. (Author, Psychotherapist)
  • Alex and Allyson Grey (Chapel Of Sacred Mirrors)
  • James Fadiman, Ph.D. (Institute of Transpersonal Psychology)
  • Ralph Metzner, Ph.D. (Green Earth Foundation)
  • Tom Pinkson, Ph.D. (Psychotherapist)
  • Thomas Roberts, Ph.D. (Northern Illinois University)

contractPresenter Application Instructions

Call For Proposals

> Download instructions as Adobe PDF or Microsoft DOC

This call for proposals details the application process to present at “Psychedelic Science in the Twenty-first Century”, a conference hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS). This document will provide an overview of what we are seeking in terms of proposals and what to expect from us after we receive your proposal.

1. Details about the conference, program, and speakers.

Psychedelic Science’s primary objective is to create a forum for scientists, medical professionals, mental health workers, and other researches to present the “state of the art” of psychedelic science. We are accepting proposals that will be well-received by both a scientific audience and an audience that is passionate about the future of psychedelics in society.

If you are chosen to present at Psychedelic Science you will present along side other experts on psychedelic science and psychedelic psychotherapy, including leading researchers who are conducting clinical studies around the world. Most researchers will present in the continuing medical education (CME) track. Physicians or ancillary medical professionals who attend presentations in the CME programming can earn CME credits; the CME track is also open to the general public to attend. It is unlikely that you will present in the CME track unless you are a medical professional with current scientific research to present.

We are planning to have a continuing education (CE) track for psychologists and related fields. We will also have a few presentations from artists or other culturally intriguing presenters, but the bulk of the presentations will be based on psychedelic science and psychedelic psychotherapy.

The conference will take place from April 15 to 18, 2009, at the Holiday Inn in San Jose, California. The conference will begin with a reception on Thursday evening, and have programming Friday through Sunday. We expect to have between 500 and 1000 attendees.

Presentations will be made in plenary sessions, panel sessions, roundtable sessions, poster presentations, and rising researchers sessions. If you are selected to present at Psychedelic Science our steering committee will have the ultimate decision as to the session format in which you will present.

Plenary sessions -- This will be a gathering of all the conference attendees (plenary sessions are reserved for a select few speakers chosen by the conference organizers).

Panel Sessions -- 2 to 4 speakers will be placed on a panel together. These sessions will last approximately 1 hour and there will be time for questions and answers from the audience.

Roundtable sessions – 4 or more speakers will present together in roundtable format. Presenters will have the opportunity to share their information followed by dialogue moderated by a knowledgeable person.

Posters presentations – an area of the conference may be designated for persons to display posters about research, hypotheses, etc.

Rising researchers panels – 4 to 6 “rising researchers,” (presenters who are relatively new to psychedelic research, often students) will present on a panel together. These sessions will last approximately 1 hour and there will be time for questions and answers from the audience.

All confirmed speakers who apply to speak through this call for proposals must register for the conference and pay the rate that applies to them at the time of registration. MAPS is waiving registration fees and paying some travel and lodging fees for speakers selected for the CME track. MAPS would love to be able to provide registration waivers and pay lodging for all of our presenters, however it simply is not economically feasible for MAPS to do so while keeping registration costs down. We will offer a limited number of discounted scholarship registrations on an as-needed basis for presenters and attendees who would otherwise not be able to attend the conference. You can request this scholarship rate on the registration page of the MAPS website. MAPS will not cover any hotel or travel costs for speakers with the exception of those were previously selected by the conference organizers.

2. Proposal Process

We encourage you to submit a proposal if you:

  • Have tested a hypothesis by collecting and analyzing data in a scientifically rigorous manner about psychedelic drugs, psychedelic experiences, or a related issue.

  • Have (a) case report(s) about psychedelic drugs or psychedelic experiences, and the report(s) would add to the body of knowledge being presented at the conference.

  • Are an expert on a therapeutic technique that is applicable to psychedelic psychotherapy.

  • Are an expert on psychedelic crisis intervention techniques.

  • Are an expert on how to help people who misuse psychedelic drugs.

  • Are an expert in a unique area related to psychedelic drugs that is not represented by other speakers.

To submit a proposal fill out the “presenter application form” in the next section. You can also download the form as a PDF or word Doc and email it to: conference2010@maps.org

or fax it to 831-429-6370

or mail it to:

MAPS
Attn: Psychedelic Science in the 21st Century
309 Cedar Street #2323
Santa Cruz, CA 95060

The proposal application form allows you to indicate whether you will use audio or visual technlogy.

We request that you attach to your application your curriculum vitae or resume and a headshot. If you cannot provide a photo at this time, we will need one shortly after your proposal is accepted. The photo needs to be at least 300 pixels per inch and a minimum of 1.5 inches wide and 2 inches tall.

3. Proposal Review Process

The conference organizers will review all presentation applications. You are welcome to submit as many proposals as you would like. The conference organizers will take into consideration your preference to speak either on a panel or in a roundtable discussion, but the final decision is up to the conference organizers. Unfortunately we may not be able to accept every application to present. The priority deadline for applications is November 30. If you have your application in by this deadline we will attempt to give you a decision within a few weeks, and will definitely give you a decision by January 31, 2010 as to whether your application is accepted. We will accept applications on a rolling basis after this deadline and review them as they come in, but there may be less space available.


contractPresenter Application Form

Proposal Submission Form

We are thrilled that you would like to present at Psychedelic Science in the Twenty-first Century. Please fill out this form. After you submit the form please email your curriculum vitae or resume, and a headshot to: conference2010@maps.org Please write your name in the subject line of the email.

> Download presenter application as Adobe PDF or Microsoft DOC. Please email the completed form to conference2010@maps.org.

Your First Name
Your Last Name
Your Email
Phone
City State/Province Postal Code
Country
ProfessionCredentials / Field-of-Study / Other Interests

Presentation Information:
  Presentation Title:  
Audio/Visual Aid needs
LCD projector and screen  
Video monitor  
Audio player  
No audio/visual technology  
Presentation type (check all that you would be willing to do)
Panel  
Roundtable  
Poster  
Rising Researchers  
Preferred length of presentation (time limits will be determined by scheduling limitations)
10 minutes  
20 minutes  
30 minutes  
More than 30 minutes  
I will be applying for a scholarship discounted registration rate on the conference registration page.
  
  Abstract of presentation (2000 character limit)

(Maximum characters: 2000)
You have characters left.
  Biography of presenter (1000 character limit)

(Maximum characters: 1000)
You have characters left.
  Added Benefit – Please tell us why you think that your presentation will be an added benefit to the conference (1000 character limit)

(Maximum characters: 1000)
You have characters left.
  Other - Is there anything else you would like our conference committee to know about you or your presentation (1000 character limit)

(Maximum characters: 1000)
You have characters left.
* I understand that if my proposal is accepted for presentation at Psychedelic Science in the 21st Century that:
  1. I am responsible to register and pay registration fees to attend the conference.
  2. If I wish to pay for the scholarship rate, I will apply for the scholarship on the conference registration page.
  3. I understand that registration fees do not include travel and lodging, and that I am responsible for my own travel and lodging fees (MAPS suggests that you stay at the conference hotel – it was chosen for reasonable prices and several meals are included in the room rate).
  4. I will present at the time allotted to me and I understand that the conference organizers will decide the time and length of my presentation. The organizers will take my preferences into consideration, but the organizers cannot make any guarantee that the length and time I request will be available.
  5. Various media outlets will be at the conference and I may appear in a news story.
  6. I will conduct myself in a respectable manner throughout the duration of the conference because as a presenter I am a representative of the conference.
  7. MAPS and their associates may video or audio record my presentation and show that presentation at a later date; I give MAPS permission to use video or audio recordings, and photographs of my presentation. I understand that no royalties will be provided and I do not stand to gain monetarily from subsequent viewings of my presentation.
  8. I will send my curriculum vitae or resume and a headshot with a minimum of 300 pixels per inch and a minimum of 1.5 inches wide and 2 inches tall attached to an email to conference2010@maps.org with my name in the subject line.

 Creative Commons 2009   MAPS   309 Cedar Street #2323   Santa Cruz, CA 95060-9989   tel: 831-429-MDMA (6362)   fax: 831-429-6370   askmaps@maps.org